Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 Versus Placebo as Part of a Treatment Regimen Including Peginterferon α-2a (Pegasys) and Ribavirin (Copegus) or Peginterferon α-2b (PegIntron) and Ribavirin (Rebetol) in Treatment-naïve, Genotype 1, Hepatitis C-infected Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms QUEST-2
- Sponsors Janssen R&D Ireland
- 09 Apr 2015 According to a Janssen Sciences media release, a multivariate analysis of this study will be presented at the European Associate for the Study of the Liver (EASL) 2015.
- 10 Oct 2014 A post-hoc analysis of pooled efficacy data from QUEST 1 and 2 was presented at the Viral Hepatitis Congress (VHC).
- 13 Apr 2014 Pooled subgroup analysis of European patients presented at the 49th Annual Meeting of the European Association for the Study of the Liver.